AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 282 min read$TEVA

Teva Pharmaceutical Industries Gains FDA Nod for Degevma Biosimi

Teva Pharmaceutical (NYSE: TEVA) received FDA approval for Degevma, a biosimilar to Xgeva, expanding its U.S. biosimilar portfolio. The company's stock is trading at $38.88, which is 133.4% above its GF Value™ of $16.66, indicating significant overvaluation. Insider activity shows $14.6M in sales over the past year. Teva's GF Score™ is 60/100, reflecting moderate financial health with strengths in profitability and momentum but concerns about valuation and financial strength.

Original reporting
gurufocus.com
Published Sep 28, 2026, 8:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$TEVA
Bullish
high confidence
Mentioned
$TEVA
Relevance
9/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The Degevma approval adds to Teva's growing biosimilar pipeline, which could improve revenue diversification beyond generics.

02

Market read

Regulatory clearance of a new oncology biosimilar is a material catalyst for Teva's stock, though valuation concerns temper enthusiasm.

03

What to watch

Potential reimbursement challenges and competition from other denosumab biosimilars could dampen long‑term impact.

Relevance 9/10Novelty 8/10Timing: same‑day announcement

Background

Teva recently received FDA clearance for Ponlimsi, another denosumab biosimilar, indicating a strategic push in this space.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

FDA approval of Degevma, a new denosumab biosimilar, expands Teva's oncology biosimilar portfolio.

Expected impact

likely modest upside as the market prices in the new product launch, though valuation concerns may cap gains.

Evidence & confidence

Regulatory clearance is a concrete catalyst; peers lack comparable recent approvals, giving Teva a relative advantage.

Market effects

Sector

Strengthens the U.S. biosimilar oncology segment, pressuring competitors to accelerate pipelines.

Regional

Positive for U.S. specialty pharma investors; limited effect on broader markets.

Global

Modest, as the product targets a niche oncology market.

Counterpoint

What could challenge this read

High valuation and weak insider buying suggest the approval may be already priced in, limiting upside.

Key entities

  • company
    Teva Pharmaceutical Industries Ltd

    Global pharmaceutical company focusing on generics and biosimilars.

  • regulator
    FDA

    U.S. Food and Drug Administration, granting the biosimilar approval.

Read at source← All news

Also covered by

6 outlets

Related articles

SEP 30
$TEVALow

Teva Pharmaceutical Names Serge Rogasik CEO of TAPI Division, Ti

Teva Pharmaceutical (TEVA) appointed Serge Rogasik as CEO of its Technology & API Services division. The company's stock is trading at $39.60, 137.8% above its GF Value™ of $16.65, indicating significant overvaluation. TEVA has a GF Score™ of 60, with strengths in profitability and momentum but weaknesses in financial strength, growth, and valuation. Insiders have sold $14.6 million in shares over the past year with no insider buying.

gurufocus.com2 min
SEP 30
$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

targetedonc.com2 min
SEP 30
$TEVAHighAI 9/10

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

biopharminternational.com2 min
SEP 30
$TEVAMedAI 9/10

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

onclive.com2 min
SEP 29
$TEVAHighAI 9/10

FDA nod for Teva’s Degevma biosimilar

Teva Pharmaceutical Industries (TEVA) received FDA approval for Degevma, a biosimilar to Amgen's Xgeva (denosumab). Degevma is indicated for preventing bone complications in advanced cancer, treating giant cell tumors, and managing hypercalcemia of malignancy. This approval expands Teva's oncology portfolio.

thepharmaletter.com2 min